Immunome (IMNM) Projected to Post Quarterly Earnings on Thursday

Immunome (NASDAQ:IMNM) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect Immunome to post earnings of ($0.72) per share and revenue of $3.16 million for the quarter.

Immunome (NASDAQ:IMNM) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16). Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. The firm had revenue of $2.74 million for the quarter, compared to the consensus estimate of $3.07 million. On average, analysts expect Immunome to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Immunome Stock Down 0.4 %

Shares of NASDAQ:IMNM opened at $8.15 on Tuesday. Immunome has a twelve month low of $8.12 and a twelve month high of $26.70. The stock’s 50 day moving average is $9.72 and its 200-day moving average is $11.49. The firm has a market capitalization of $650.18 million, a price-to-earnings ratio of -1.00 and a beta of 1.93.

Insider Activity

In other Immunome news, CEO Clay B. Siegall purchased 150,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The stock was bought at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the completion of the transaction, the chief executive officer now owns 669,636 shares of the company’s stock, valued at $5,189,679. The trade was a 28.87 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 8.60% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Stephens restated an “overweight” rating and set a $30.00 price objective on shares of Immunome in a report on Thursday, March 20th. Guggenheim lowered their target price on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, March 20th. Lifesci Capital assumed coverage on Immunome in a research note on Tuesday, March 11th. They set an “outperform” rating and a $20.00 price target for the company. Finally, Wedbush reissued an “outperform” rating and set a $33.00 price objective on shares of Immunome in a report on Thursday, March 20th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Immunome currently has an average rating of “Buy” and a consensus target price of $25.50.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.